SUPREFACT INJ 1MG/ML 1 MG
BUSERELIN (BUSERELIN ACETATE) : 1 MG · DIN 00680028 · HOECHST CANADA INC.
Health Canada status: CANCELLED POST MARKET
What is SUPREFACT INJ 1MG/ML?
SUPREFACT INJ 1MG/ML 1 MG contains BUSERELIN (BUSERELIN ACETATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 00680028, held by HOECHST CANADA INC., supplied as LIQUID for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 25-Aug-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00680028 |
|---|---|
| Brand name | SUPREFACT INJ 1MG/ML |
| Generic / active ingredient | BUSERELIN (BUSERELIN ACETATE) : 1 MG |
| Manufacturer | HOECHST CANADA INC. |
| Strength | 1 MG |
| Dosage form | LIQUID |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L02AE01 BUSERELIN |
| AHFS class | 92:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 25-Aug-1998 |
| Original market date | 1988-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code L02AE01 BUSERELIN. 1 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SUPREFACT | 1 MG | SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 02225166 |
| SUPREFACT | 100 MCG | SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | CANCELLED POST MARKET | DIN 02225158 |
| SUPREFACT DEPOT 2 MONTHS | 6.3 MG | IMPLANT | CHEPLAPHARM ARZNEIMITTEL GMBH | DORMANT | DIN 02228955 |
| SUPREFACT DEPOT 3 MONTHS | 9.45 MG | IMPLANT | CHEPLAPHARM ARZNEIMITTEL GMBH | DORMANT | DIN 02240749 |
| SUPREFACT INTRANASAL SOLUTION 1MG/ML | 1 MG | SPRAY | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00680036 |
| SUPREFACT LIQ 1MG/ML | 1 MG | LIQUID | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | DIN 01989669 |
Who else supplies BUSERELIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUSERELIN appears in 10 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.